Ohio is currently home to 3212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Academic-Community EPINET (AC-EPINET)
NCT04497857
Recruiting
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
Gender:
ALL
Ages:
Between 16 years and 35 years
Trial Updated:
09/17/2024
Locations: The Early Psychosis Intervention Center (EPICENTER) at Ohio State, Columbus, Ohio
Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Aultman Alliance Community Hospital, Alliance, Ohio
Conditions: Ovarian Carcinoma
Register for Updates
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
NCT03630536
Recruiting
There are limited data regarding the biology and treatment of TFE Renal Cell Carcinoma (TFE RCC). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of TFE RCC. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with TFE RCC, prospectively. Cases are identified through: 1. Existing clinical and/or cancer... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Renal Cell Carcinoma
Register for Updates
Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion
NCT03063892
Recruiting
Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
09/17/2024
Locations: ProMedica Toledo Hospital, Toledo, Ohio
Conditions: Hip Fractures
Register for Updates
High-Fidelity Patient Simulation on Clinical Reasoning Skills and Interprofessional Competencies
NCT06549998
Recruiting
The proposed study is looking to examine the effects of High-Fidelity Patient Simulation (HFPS) on clinical reasoning skills and interprofessional competencies in Physical Therapy and Nursing students. The proposed study will have two objectives: 1. Assess the use of HFPS and whether it has an effect of improving physical therapy and nursing student performance related to clinical reasoning skills during simulated clinical situations. 2. Assess the use of HFPS and whether it has an effect of i... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/16/2024
Locations: Youngstown State University, Youngstown, Ohio
Conditions: Healthy
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
NCT06493578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/16/2024
Locations: DOCS Dermatology Research - Canal Winchester, Canal Winchester, Ohio
Conditions: Non-segmental Vitiligo
Register for Updates
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805
Recruiting
This phase II trial compares the effect of relugolix to leuprolide on cardiac function and performance in patients with prostate cancer. Androgen deprivation therapy (ADT) has been a key component for the treatment of advanced prostate cancer for decades. The term androgen deprivation therapy means lowering a man's testosterone. Long-term studies show that ADT may contribute to a detriment to cardiac health and predisposes men to developing cardiac diseases. Recent studies suggest that men takin... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Register for Updates
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377
Recruiting
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/16/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Sickle Cell Trait
Register for Updates
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714
Recruiting
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Advanced Solid Tumor, Breast Cancer
Register for Updates
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
NCT04730258
Recruiting
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Register for Updates
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
NCT03935984
Recruiting
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: ProMedica Toledo Hospital, Toledo, Ohio
Conditions: Primary Hyperparathyroidism, Hypercalcemia
Register for Updates
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
09/16/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Pompe Disease (Late-onset)
Register for Updates